| Khaja Tajuddin Faisal, MD | |
|
300 Clocktower Dr, Hamilton, NJ 08690-3010 | |
| (609) 683-3283 | |
| (609) 683-3291 |
| Full Name | Khaja Tajuddin Faisal |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 29 Years |
| Location | 300 Clocktower Dr, Hamilton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366562902 | NPI | - | NPPES |
| 0181463 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 25MA08215400 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hunterdon Medical Center | Flemington, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hunterdon Specialty Care Pc | 4587966601 | 83 |
| Hunterdon Medical Center | 9830009711 | 73 |
News Archive
Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).
The Washington Post examines the landmines associated with these statistics. Meanwhile, Bloomberg reports on a new lawsuit in which a man claims Humana raised his premiums and then refused to honor his request to cancel the policy.
The study is being published in an advanced online edition of the Proceedings of the National Academy of Sciences.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
The president is expected today to nominate Bob McDonald, a West Point graduate and former CEO of Procter & Gamble.
› Verified 8 days ago
| Entity Name | Hunterdon Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629130307 PECOS PAC ID: 9830009711 Enrollment ID: O20040508000014 |
News Archive
Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).
The Washington Post examines the landmines associated with these statistics. Meanwhile, Bloomberg reports on a new lawsuit in which a man claims Humana raised his premiums and then refused to honor his request to cancel the policy.
The study is being published in an advanced online edition of the Proceedings of the National Academy of Sciences.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
The president is expected today to nominate Bob McDonald, a West Point graduate and former CEO of Procter & Gamble.
› Verified 8 days ago
| Entity Name | Princeton Healthcare Affiliated Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518194323 PECOS PAC ID: 2567598022 Enrollment ID: O20100413000141 |
News Archive
Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).
The Washington Post examines the landmines associated with these statistics. Meanwhile, Bloomberg reports on a new lawsuit in which a man claims Humana raised his premiums and then refused to honor his request to cancel the policy.
The study is being published in an advanced online edition of the Proceedings of the National Academy of Sciences.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
The president is expected today to nominate Bob McDonald, a West Point graduate and former CEO of Procter & Gamble.
› Verified 8 days ago
| Entity Name | Princeton House Provider Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881078681 PECOS PAC ID: 0244540540 Enrollment ID: O20151116001851 |
News Archive
Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).
The Washington Post examines the landmines associated with these statistics. Meanwhile, Bloomberg reports on a new lawsuit in which a man claims Humana raised his premiums and then refused to honor his request to cancel the policy.
The study is being published in an advanced online edition of the Proceedings of the National Academy of Sciences.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
The president is expected today to nominate Bob McDonald, a West Point graduate and former CEO of Procter & Gamble.
› Verified 8 days ago
| Entity Name | Hunterdon Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306216874 PECOS PAC ID: 4587966601 Enrollment ID: O20160106002688 |
News Archive
Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).
The Washington Post examines the landmines associated with these statistics. Meanwhile, Bloomberg reports on a new lawsuit in which a man claims Humana raised his premiums and then refused to honor his request to cancel the policy.
The study is being published in an advanced online edition of the Proceedings of the National Academy of Sciences.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
The president is expected today to nominate Bob McDonald, a West Point graduate and former CEO of Procter & Gamble.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Khaja Tajuddin Faisal, MD 300 Clocktower Dr, Hamilton, NJ 08690-3010 Ph: (609) 683-3283 | Khaja Tajuddin Faisal, MD 300 Clocktower Dr, Hamilton, NJ 08690-3010 Ph: (609) 683-3283 |
News Archive
Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).
The Washington Post examines the landmines associated with these statistics. Meanwhile, Bloomberg reports on a new lawsuit in which a man claims Humana raised his premiums and then refused to honor his request to cancel the policy.
The study is being published in an advanced online edition of the Proceedings of the National Academy of Sciences.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
The president is expected today to nominate Bob McDonald, a West Point graduate and former CEO of Procter & Gamble.
› Verified 8 days ago
Dr. Christi Ann Weston, M.D., PH.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1445 Whitehorse Mercerville Rd Ste 111, Hamilton, NJ 08619 Phone: 609-689-5725 Fax: 609-689-5726 | |
David Bresch, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1225 Whitehorse Mercerville Rd, Building D, Suite 203, Hamilton, NJ 08619 Phone: 609-581-6087 Fax: 609-581-9561 | |
Dr. Chirag S. Shukla, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1445 Whitehorse Mercerville Rd Ste 104, Hamilton, NJ 08619 Phone: 609-537-7300 Fax: 609-537-7301 | |
Liren Li, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3575 Quakerbridge Rd, Hamilton, NJ 08619 Phone: 609-631-2800 | |
Dr. Elvira Downs, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3575 Quakerbridge Rd, Hamilton, NJ 08619 Phone: 609-631-2800 | |
Dr. James A Ware Jr., M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 396 Whitehorse Ave, Hamilton, NJ 08610 Phone: 609-585-0118 Fax: 609-585-0244 |